ArticleEpilepsia2026
Introducing the D-DAND scale: Development of a comprehensive caregiver-administered tool for Dravet syndrome comorbidities.
Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe Dravet Disease-Associated Neuropsychiatric Disorders (D-DAND) scale is a new caregiver-administered interview designed to assess the wide range of developmental and behavioral comorbidities in Dravet syndrome (DS) beyond seizures. D-DAND's preliminary psychometric properties in a large patient sample are reported.
methodsD-DAND was developed by a panel of experts and later standardized with caregivers of 123 individuals with DS (age = 3-41 years); a subsample of 43 caregivers were interviewed twice (~2 weeks apart) to evaluate test-retest reliability; another subsample of 80 were also administered with other scales that are widely used despite not being tailored to DS (Vineland Adaptive Behavior Scales, Child Behavior Checklist, Childhood Autism Rating Scale, Behavior Rating Inventory of Executive Function, Sleep Disturbance Scale for Children).
resultsThe D-DAND captured a broad spectrum of abilities and dysfunctions across multiple functional domains. Test-retest reliability was excellent (overall score: r ≈ .98, median across domains: r ≈ .89), thus allowing for high sensitivity to time-related changes. As expected, D-DAND scores showed high correlations with some standardized measures (e.g., Vineland scales) and low correlation with others, suggesting that D-DAND measures unique, Dravet-specific features that other, widely used tools fail to detect. SIGNIFICANCE: D-DAND is a novel, reliable tool for comprehensive evaluation of DS beyond seizures. It enables systematic tracking of developmental and behavioral issues in DS, facilitating early identification of needs and more personalized, whole-person care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.